MAPK3 and lymphoma: It has been reported that rituximab induces apoptosis in lymphoma cells by inhibiting various antiapoptotic constitutively activated signaling pathways, such as NF-κB, p38 MAPK, ERK1/2, AKT, Bcl-2, and Bcl-xL [43].